Search research articles
Contact Us
Filters
Showing results (741-750 of 903) with videos related to
Page
of 91
Sort By:
Blood
|
June 29, 2012
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
Emilia Mahoney, David M Lucas, Sneha V Gupta, et al.
The Journal of Clinical Investigation
|
August 25, 2007
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
Paolo Neviani, Ramasamy Santhanam, Joshua J Oaks, et al.
Leukemia
|
January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies
Nadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.
Blood Advances
|
July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Alison R Walker, Guido Marcucci, Jun Yin, et al.
Blood
|
November 15, 2008
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
Farrukh T Awan, Neil E Kay, Melanie E Davis, et al.
Blood
|
November 5, 2008
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
Mitch A Phelps, Thomas S Lin, Amy J Johnson, et al.
The Journal of Experimental Medicine
|
April 24, 2013
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
Flavia Pichiorri, Dario Palmieri, Luciana De Luca, et al.
Leukemia & Lymphoma
|
March 9, 2017
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
Douglas W Sborov, Alessandro Canella, Erinn M Hade, et al.
American Journal of Hematology
|
September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir, Jennifer R Brown, Susan O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Sarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.
Page
of 91
Search research articles
Search
Showing results (741-750 of 903) with videos related to
Sort By:
Page
of 91
Blood
|
June 29, 2012
ER stress and autophagy: new discoveries in the mechanism of action and drug resistance of the cyclin-dependent kinase inhibitor flavopiridol
Emilia Mahoney, David M Lucas, Sneha V Gupta, et al.
The Journal of Clinical Investigation
|
August 25, 2007
FTY720, a new alternative for treating blast crisis chronic myelogenous leukemia and Philadelphia chromosome-positive acute lymphocytic leukemia
Paolo Neviani, Ramasamy Santhanam, Joshua J Oaks, et al.
Leukemia
|
January 13, 2025
Prognostic, biological, and structural implications of FLT3-JMD point mutations in acute myeloid leukemia: an analysis of Alliance studies
Nadeen Anabtawi, Deedra Nicolet, Najla Alotaibi, et al.
Blood Advances
|
July 12, 2021
Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)
Alison R Walker, Guido Marcucci, Jun Yin, et al.
Blood
|
November 15, 2008
Mcl-1 expression predicts progression-free survival in chronic lymphocytic leukemia patients treated with pentostatin, cyclophosphamide, and rituximab
Farrukh T Awan, Neil E Kay, Melanie E Davis, et al.
Blood
|
November 5, 2008
Clinical response and pharmacokinetics from a phase 1 study of an active dosing schedule of flavopiridol in relapsed chronic lymphocytic leukemia
Mitch A Phelps, Thomas S Lin, Amy J Johnson, et al.
The Journal of Experimental Medicine
|
April 24, 2013
In vivo NCL targeting affects breast cancer aggressiveness through miRNA regulation
Flavia Pichiorri, Dario Palmieri, Luciana De Luca, et al.
Leukemia & Lymphoma
|
March 9, 2017
A phase 1 trial of the HDAC inhibitor AR-42 in patients with multiple myeloma and T- and B-cell lymphomas
Douglas W Sborov, Alessandro Canella, Erinn M Hade, et al.
American Journal of Hematology
|
September 13, 2019
Final analysis from RESONATE: Up to six years of follow-up on ibrutinib in patients with previously treated chronic lymphocytic leukemia or small lymphocytic lymphoma
Talha Munir, Jennifer R Brown, Susan O'Brien, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
December 2, 2016
The Bruton Tyrosine Kinase (BTK) Inhibitor Acalabrutinib Demonstrates Potent On-Target Effects and Efficacy in Two Mouse Models of Chronic Lymphocytic Leukemia
Sarah E M Herman, Arnau Montraveta, Carsten U Niemann, et al.
Page
of 91